Time
July 2, 2026 (Thursday)
1:00-2:30 PM (UTC+1)
3:00-4:30 PM (UTC+3)
8:00-9:30 PM (UTC+8)
1:00-2:30 PM (UTC+1)
3:00-4:30 PM (UTC+3)
8:00-9:30 PM (UTC+8)
Moderator
Dr. Shuai Ren
Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Scopus: https://www.scopus.com/pages/authors/57195058841
Research Interest: Gastrointestinal tumors, nanodrug delivery, tumor immunology, exosomes, extracellular vesicles, molecular probes
Research Interest: Gastrointestinal tumors, nanodrug delivery, tumor immunology, exosomes, extracellular vesicles, molecular probes
Speaker(s)
Prof. Martin Michaelis
University of Kent, Canterbury, United Kingdom.
Scopus: https://www.scopus.com/pages/authors/34571115900
Research Interest: Drugs and mechanisms of action, acquired drug resistance in cancer, therapeutic targets
Research Interest: Drugs and mechanisms of action, acquired drug resistance in cancer, therapeutic targets
Dr. Yuxuan Song
Peking University People's Hospital, Beijing, China.
Scopus: https://www.scopus.com/pages/authors/57203822723
Research Interest: Urologic cancers, spatiotemporal multi-omics, organoids, immunotherapy, large language models (LLMs)
Research Interest: Urologic cancers, spatiotemporal multi-omics, organoids, immunotherapy, large language models (LLMs)
Prof. Nadia M. Hamdy
Ain Shams University, Cairo, Egypt.
Scopus: https://www.scopus.com/authid/detail.uri?authorId=57190847144
Research Interest: (Epi)genetic regulation of cancer, tumor microenvironment, and precision oncology, signaling pathways in cancer, biomarkers for diagnosis and prognosis, translational cancer therapeutics
Research Interest: (Epi)genetic regulation of cancer, tumor microenvironment, and precision oncology, signaling pathways in cancer, biomarkers for diagnosis and prognosis, translational cancer therapeutics
Programme
Programme
| Time (UTC+8) | Moderator / Speakers | Topic |
|---|---|---|
| 8:00-8:10 PM | Shuai Ren | Welcoming Address |
| 8:10-8:25 PM | Martin Michaelis | Drug-induced heterogeneity and its implications for personalised therapies |
| 8:25-8:30 PM | Q&A session I | |
| 8:30-8:45 PM | Yuxuan Song | Investigation of Therapeutic Drug Strategies for Bladder Cancer from Multi-evidence Perspectives |
| 8:45-8:50 PM | Q&A session II | |
| 8:50-9:05 PM | Nadia M. Hamdy | Treatment of Non-Small Cell Lung Cancer Using Chem-Bioinformatics-Driven Engineering of Exosomal Cargo-Vehicle for Telmisartan and Pioglitazone Targeted-Delivery |
| 9:05-9:10 PM | Q&A session III | |
| 9:10-9:15 PM | Shuai Ren | Conclusion |
Presentation
Moderator Dr. Shuai Ren introduces the CDR journal and the specific process of this webinar
NaN
Prof. Martin Michaelis-Drug-induced heterogeneity and its implications for personalised therapies
NaN
Dr. Yuxuan Song-Investigation of Therapeutic Drug Strategies for Bladder Cancer from Multi-evidence Perspectives
NaN
Prof. Nadia M. Hamdy-Treatment of Non-Small Cell Lung Cancer Using Chem-Bioinformatics-Driven Engineering of Exosomal Cargo-Vehicle for Telmisartan and Pioglitazone Targeted-Delivery
NaN
